ifcg: a promising new regimen for treating ighv-mutated cll
Published 7 years ago • 347 plays • Length 1:35Download video MP4
Download video MP3
Similar videos
-
8:33
boven regimen for previously untreated cll: long-term follow-up and mrd kinetics
-
1:05
long-term outcomes of patients with cll treated with continuous ibrutinib
-
2:19
long-term management of cll for improved outcomes
-
1:37
long-term follow-up from a phase ii trial of olutasidenib in idh1-mutated aml
-
8:57
outcomes of sct in t-all and t-lbl
-
2:10
a study investigating the incidence of treatment-emergent autoimmune cytopenias in cll
-
2:42
ifcg yields unprecedented mrd negativity in cll
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
5:22
magrolimab azacitidine in mds and aml
-
8:10
e c l t test form 132 _ englsih test form 132 with answers .
-
2:51
world's long tallest ice cream - cost only $4.28
-
1:16
current and future advancements in the treatment of cll
-
2:24
prevalence of btk and plcγ2 mutations in cll relapsing under ibrutinib
-
1:34
time-limited vs continuous therapy in cll treatment
-
4:25
cll: state of the art in italy
-
3:32
efficacy and tolerability results from a phase i/ii study of loxo-305 in b-cell malignancies
-
2:02
key questions about the future of cll
-
2:46
challenges in the use of btk inhibitors for cll
-
2:51
key btk inhibitor trials for the initial treatment of cll
-
2:15
cd8 t cell expansion in cll patients treated with ibrutinib
-
2:41
btk and plcg2 mutations in cll patients taking ibrutinib
-
1:09
cll treatment: discussing new data from the last 3 years